LABLAB offers a focused portfolio of molecular diagnostic solutions for oncology and hematology, including assays for hematological malignancies, myeloproliferative neoplasms, leukemia monitoring and selected solid tumor applications.
Our portfolio includes solutions from Optolane and Biotype, covering technologies such as digital PCR, real-time PCR and molecular assay systems designed for clinical and research laboratory workflows.
Optolane provides molecular diagnostic solutions based on advanced digital PCR technology. The platform is particularly relevant for applications requiring high sensitivity, precise quantification and reliable detection of low-frequency molecular targets.
Within hematology and oncology, Optolane offers assays for key molecular markers such as:
BCR::ABL1 Major and Minor
Relevant for molecular testing and monitoring in chronic myeloid leukemia and selected acute leukemias.
KRAS – BRAF – HER2 CNV analysis
Molecular analysis of KRAS, BRAF and HER2 copy number variation (CNV) is relevant in selected solid tumor diagnostics, where detection of clinically important mutations and gene amplification may support tumor characterization, treatment stratification and therapy monitoring.
Additional molecular oncology markers
Depending on the assay menu, Optolane solutions may also be relevant for mutation detection and quantification in oncology-related applications.
Optolane’s technology is well suited for laboratories looking for sensitive, quantitative molecular testing with a streamlined workflow.
Biotype offers a focused portfolio of molecular diagnostic assays for hemato-oncology, solid tumor profiling and molecular cancer diagnostics. The products are designed to support laboratories working with clinically relevant biomarkers, including mutation analysis, gene fusions, microsatellite instability and copy number variation.
Within hemato-oncology, Biotype provides solutions for AML-related molecular testing, including assays for the detection of relevant gene fusions and mutations associated with acute myeloid leukemia. These products may support molecular characterization, risk stratification and investigation of clinically relevant genetic alterations.
For solid tumor applications, Biotype offers assays for molecular profiling of selected cancer biomarkers, including MSI analysis, POLE/POLD1, FGFR alterations and copy number variation testing. These assays may be relevant for laboratories working with tumor classification, therapy stratification and molecular pathology workflows.
Biotype’s products are relevant for clinical laboratories, molecular pathology departments and research laboratories seeking robust molecular assays for oncology and hemato-oncology applications.
